What is already known about this subject? ► The most recent large scale population estimates of the incidence and prevalence of polymyalgia rheumatica were published in 2006 and no similar sized estimates exist of the duration of glucocorticoid treatment in patients with this condition.
How might this impact on clinical practice or future developments?
► These findings will prompt further work to identify those at risk of prolonged glucocorticoid treatment and its inherent risks.
AbsTrACT
Objective polymyalgia rheumatica (pMr) is the most common inflammatory rheumatic disease in older people. Contemporary estimates of the incidence and prevalence are lacking, and no previous study has assessed treatment patterns at a population level. this study aims to address this. Methods We extracted anonymised electronic medical records of patients over the age of 40 years from the Clinical practice research datalink in the period 1990-2016. the absolute rate of pMr per 100 000 person-years was calculated and stratified by age, gender and calendar year. Incidence rate ratios were calculated using a poisson regression model. Among persons with pMr, continuous and total duration of treatment with glucocorticoids (GC) were assessed. results 5 364 005 patients were included who contributed 44 million person-years of follow-up. 42 125 people had an incident diagnosis of pMr during the period. the overall incidence rate of pMr was 95.9 per 100 000 (95% CI 94.9 to 96.8). the incidence of pMr was highest in women, older age groups and those living in the South of England. Incidence appears stable over time. the prevalence of pMr in 2015 was 0.85 %. the median (IQr) continuous GC treatment duration was 15.8 (7.9-31.2) months. However, around 25% of patients received more than 4 years in total of GC therapy.
Conclusions the incidence rates of pMr have stabilised. this is the first population-based study to confirm that a significant number of patients with pMr receive prolonged treatment with GC, which can carry significant risks. the early identification of these patients should be a priority in future research.
InTrOduCTIOn
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting older people. Its impact on patients' lives can be devastating, causing stiffness, severe pain and significant impairment to daily activities. 1 Glucocorticoids (GCs) remain the mainstay of treatment. 2 The incidence and prevalence of PMR vary depending on geography; as latitude increases, so do PMR rates. 3 Previous studies have estimated the prevalence of PMR to lie between 0.1% and 1% 4 5 and the incidence between 12 and 113 per 100 000 person-years. [6] [7] [8] The majority of cases of PMR are treated in primary care (71%-84%) 7 9 ; however, much of the existing literature is based on secondary care hospital records. Therefore the burden of disease may have been underestimated. One large study (Smeeth et al 10 ) used primary care data to estimate the incidence of PMR, reporting an overall rate of 84 per 100 000 person-years, which was increasing with time. However, the final year of data published in this study was 2001; therefore, more contemporaneous estimates of national data are needed to guide health service provision.
PMR is managed with gradually reducing GC therapy, from moderate to low doses. 3 Joint guidance released by the American College of Rheumatology and the European League Against Rheumatism advises GC treatment for most patients with PMR should end by 2 years. 2 However, it has been suggested a large proportion of patients experience symptom flare on cessation, or even reduction, of GC therapy (a 'symptom tail').
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The aims of this study are to quantify the overall incidence and prevalence of PMR in the UK using a large population-based database and to investigate prescribing of GCs in those diagnosed with PMR.
MeTHOds data source and study population
Almost all healthcare in the UK is delivered by the National Health Service (NHS), a public system funded by taxation that provides free, or low-cost, healthcare to all residents. Around 90% of patient contacts in the UK with the NHS is via primary care, 12 and 98% of people who live in the UK are registered with a general practice. We used data from the Clinical Practice Research Datalink (CPRD; July 2017 version), which contains data for around 17 million contributing patients within 718 (7.5% of the total) UK general practices. This database, containing electronic, coded information collected during the course of routine healthcare, is representative of the UK population in terms of age, sex and ethnicity, 13 and has been used extensively for primary care research.
Incidence
We analysed data collected between 1 January 1990 and 1 January 2016. Patients contributed data after the latest of four events: (1) the study start date, (2) the date at which they became 40 years old, (3) the date they registered at a participating practice plus 6 months, or (4) the date at which the practice was adjudged to reach internal quality standards, known as the 'up-to-standard' date.
The date at which each follow-up ended was the earliest of five events: (1) the end of study period (1 January 2016), (2) the date when a patient transferred out of a practice, (3) the date of death, (4) the last date of data collection from the practice or (5) the date when they were diagnosed with PMR.
Patients with a Read-coded diagnosis of PMR (codes: N20.00 Polymyalgia rheumatica, N200.00 Giant cell arteritis with polymyalgia rheumatica) in their general practice record were included as incident cases. The first 6 months following registration with a practice were excluded from the incidence analysis to avoid inclusion of prevalent cases which may have been incorrectly recorded at the point of registration. 10 To improve case ascertainment, we only considered PMR diagnosis to be valid if patients received at least two prescriptions for oral GCs: one within 6 months of the diagnosis date and the second within 6 months of the first prescription. 10 Patients could have a diagnosis of both PMR and giant cell arteritis (GCA). We looked only at the first occurrence of PMR; therefore, all subsequent person-time and diagnostic codes were excluded. This process is summarised in online supplementary figure 1.
Treatment of PMr
To ascertain trends in the management of PMR, we assessed patterns of GC prescribing in the incident cases of PMR. All GC prescriptions recorded in CPRD using medications from the British National Formulary (BNF) chapter 6.3.2 'Glucocorticoid therapy' were included.
14 CPRD contains information about the quantity of medication prescribed, the number of units of medication to be taken each day and the prescription duration. The algorithm used to define duration and dose of GC therapy (detailed in online supplementary figure 2) has been defined elsewhere. 15 KaplanMeier survival methods were used to calculate the median duration of time from diagnosis until completion of continuous GC therapy. The end of a treatment course was determined to have occurred when no further GC prescriptions occurred for 90 days after the calculated duration of the previous prescription. Patients were censored if they were lost to follow-up prior to stopping treatment. The 90-day period was chosen as it is the same as in previous CPRD-based studies of medication use. 16 As part of a sensitivity analysis, we recalculated this duration (1) by increasing the interval between prescriptions to 6 months; or (2) in patients who received a diagnosis with another rheumatological condition either prior to PMR diagnosis or in the 2 years subsequently; or (3) were referred to secondary care rheumatology services.
statistical analysis
Crude incidence rates of PMR were calculated by dividing the total number of new cases by the total person-years of follow-up per 100 000 person-years. Incidence rates were stratified by age, gender, region and calendar year. Patient age was grouped into decades. Lexis expansion 17 was used to calculate incidence rates by year following the study start date of 1 January 1990.
To compare the absolute rate of PMR by patient characteristics, we used a Poisson regression model and calculated the incidence rate ratios (IRR) for each covariate, including sex, age, region and calendar year of diagnosis. Age-adjusted incidences for each covariate were calculated with direct standardisation, using the sample population structure over the whole study.
For treatment pattern analysis, we calculated the average daily and total dose of GC prescribed, as well as the cumulative treatment time and the total number of prescriptions and separate treatment courses each patient received. Dosage calculations were made by converting the strength of all medications to milligrams of prednisolone equivalent using the BNF conversion tables of equivalent anti-inflammatory doses.
14 Results were stratified by starting GC dose, age and sex.
Point prevalence of PMR was calculated for each calendar year by dividing the total number of patients who have received a diagnosis of PMR at any time in the past and were alive and contributing data on 31 December of that year (numerator) by the total number of patients alive and contributing data on that date (denominator), thereby including incident and prevalent cases. As part of sensitivity analysis, we recalculated the prevalence in patients aged over 55 years in order to compare with a recent study. 9 Statistical analyses were conducted using Stata V.15.1.
resulTs

Overall incidence
A total of 5 364 005 individuals contributed 43.97 million person-years of follow-up in the period 1990-2016. The total number of new occurrences of PMR that fulfilled the GC prescription criteria was 42 145. This equated to 90.4% of the total number of PMR cases recorded during this time. The overall incidence rate of PMR among patients aged 40 years and over was 95.9 (95% CI 94.9 to 96.8) per 100 000 person-years (table 1). The incidence rates were significantly higher at older ages: those aged >70 years were around 10 times (IRR=9.61 (95% CI 9.25 to 9.98)) more likely to have PMR compared with those between the ages of 50 and 59 years. Women were 67% more likely to develop PMR compared with men (IRR=1.67 (95% CI 1.64 to 1.71)). A marked variation in incidence rates by region was found (figure 1), with rates highest in the south-west region of the UK (124.1 (95% CI 120.6 to 127.6)) and lowest in the north-east (65 (95% CI 59.5 to 70.9)).
Incidence of PMr over time
The variation in incidence rates of PMR over time is displayed in table 2 and figure 2. The rate of diagnosis of PMR dipped a little after 1990 until 1996 before increasing significantly until just after the end of the last century; after this the rate of diagnosis of PMR remained relatively stable between 2003 and 2014.
GC prescribing in PMr
In total 1 242 841 GC prescriptions were issued to patients after a diagnosis with PMR; of these 99.9% contained Clinical and epidemiological research information about quantity of medication prescribed and 48.3% about numeric daily dose. The median time taken for patients to stop continuous therapy was 1.31 years (IQR 0.65-2.6) ( figure 3 ). When the treatment gap was increased to 6 months, this increased to 1.88 years (0.93-4.00). When the total GC treatment time was reviewed, the median duration increased further to 1.93 years (0.95-4.03), meaning around 25% of patients received more than 4 years of therapy. Among patients with a rheumatology diagnosis, or those referred to rheumatology, the median continual duration of GC therapy was greater at 1.49 (IQR 0.73-3.16) and 1.55 (IQR 0.79-3.06) years, respectively. The median first and average daily doses of GC received (in milligrams of prednisolone equivalent) were 15 mg (IQR 8-21) and 6 mg (IQR 4-9), respectively. However, 7138 (16.9%) patients received on average greater than 10 mg GC per day. The median total dose of GC received (in grams of prednisolone equivalent) was 4 g (IQR 2-8). Repeating analyses stratified by initial GC dose, age and sex were unremarkable, with only patients aged under 50 receiving significantly fewer prescriptions.
Prevalence of PMr
The point prevalence of PMR in 2015 among patients aged over 40 years was 0.85% (table 2) and was markedly different between men and women (0.6% and 1.16%). The prevalence increased to 1.7% (95% CI 1.69% to 1.71%) in patients aged over 55 years.
dIsCussIOn
Main findings
This study estimates the burden of PMR in the UK to be slightly higher than previously estimated. In 2015 around 1 in 120 adults aged over 40 have received a diagnosis of PMR. Overall, the incidence of PMR during the study period 1990-2016 was 95.9 per 100 000 person-years (95% CI 94.9 to 96.8). However, after increasing until 2002, the incidence rate of PMR has stabilised. Almost 50% of patients with PMR received more than 2 years of GC therapy following diagnosis, despite guidelines suggesting treatment should have ended.
strengths and limitations
We have conducted the largest study yet to calculate a true estimate of the current incidence, prevalence and real-world treatment patterns of patients with PMR. This study uses robust methodology in a large, established database of patients who are representative of the UK population. It therefore is likely to be an accurate estimate of the true burden of PMR. Most patients with PMR are managed exclusively in primary care 7 9 ; therefore, this is the most appropriate setting to conduct this study.
A potential limitation is the ascertainment of cases. This was based on medical codes recorded by the primary care physicians, rather than research classification criteria, 18 as there is no sufficient detail in medical records and therefore CPRD to allow this. Patients may therefore subsequently be diagnosed with an alternative condition. However, using GC prescriptions to confirm PMR diagnosis is well established. 10 19 Greater than 90% of patients with a diagnosis of PMR received at least two GC prescriptions, showing the diagnosis is likely to be accurate in the vast majority of patients. Furthermore, in the UK diagnoses made in secondary care are communicated to, and recorded in, primary care. Therefore although this study examined patients in primary care, it will also contain information from secondary care.
Comparison with other studies
The highest incidence, 113 per 100 000 patients, previously reported was a study from the South West of England. 4 Although the overall incidence rate we found is lower than this, our estimate for this region was slightly higher (124.1 (120.6, 127.6)). In the USA, the most recent estimate of PMR rate reported by Raheel et al 8 was 63.9 per 100 000. This is lower than our figure. However, this study was not conducted in primary care, and stricter diagnostic criteria rather than codes were used. 20 We included patients from a much larger sample, and while our PMR definition is not ideal our estimates are broadly in line with other studies that have used clinical classification criteria. Therefore we believe that the risk of misclassification is minimal.
Women were more likely to develop PMR, with a female to male ratio of approximately 2:1, reflecting previous studies. 10 The strong association between older age and risk of developing PMR has been demonstrated before, with other studies reporting a median age at diagnosis of 70 9 or 75 years. 7 As rates of frailty, aches, pains 21 and erythrocyte sedimentation rate (ESR) measurements 22 increase with age, it is possible that primary care physicians may overdiagnose PMR in at least some of these patients.
The prevalence of PMR has been found to vary between 0.1% and 1% in North Europe and North America. 4 23 The prevalence of 0.85% in 2015 calculated in our study is consistent with this. In a recent study in a single large GP practice in the south of the UK, Yates et al 9 reported a prevalence of 2.27% in those aged 55 years and over. In our data, the prevalence in this group was 1.7%. This discrepancy could be explained by the higher incidence of PMR in the south and east of the UK. Given PMR is known to preferentially affect people of Northern European descent, these results are likely to be generalisable to countries with significant number of people from this ethnic group. However, the incidence and prevalence figures reported in this study are less generalisable to countries at lower latitudes, as incidence and prevalence rates have been found to reduce with decreasing latitude. 5 24 25 The incidence of PMR appears higher in the south of the UK compared with the north. This was also demonstrated by Smeeth et al. 10 Genetic associations between specific human leucocyte antigen molecules and GCA have been found, 26 although none yet for PMR. 27 However, as no major variation has been found in the genetic make-up of people between different regions around the UK, it is unlikely to be the reason for this difference. 28 Other potential reasons include an association between social class and PMR, a viral aetiological agent, or environmental differences such as reduced vitamin D levels in the north of the UK due to less sunlight exposure, which may lead to vitamin D deficiency being diagnosed preferentially.
Smeeth et al 10 found that the incidence of PMR in the UK was increasing until 2001, which we replicated. However following this date, the incidence rate plateaued.
With regard to GC therapy, 75% received a first dose between 8 and 21 mg, which corresponds well to the recommended starting dose of 12.5-25 mg. 2 The median duration of treatment of patients with GC in our sample is, however, less than that found by Shbeeb et al 29 in their recent study into GC prescribing in a cohort of 359 patients with PMR in Olmsted County, Minnesota. The median dose prescribed was similar, at around 5 mg, but the length of treatment was greater, with only 19% of patients discontinuing therapy in the first year of treatment, compared with 27% in our data. A number of reasons for this difference could be suggested; for example, their patients may represent more severe variants of the condition; they defined end of treatment as permanent discontinuation of GC therapy rather than a gap of 90 days or 6 months; and their inclusion criteria were stricter. Therefore some of the patients included in our study may have gone on to be reclassified with a different condition and have GC therapy curtailed earlier. Our sensitivity analyses of patients who had a record of referral to secondary care rheumatology services confirmed this group had longer continuous and total treatment. Both studies agreed though that a significant proportion of patients were subject to prolonged treatment with GCs.
Previous studies have shown that long-term GC treatment increases a person's risk of a wide range of medical conditions. 22 This is the first study of a large population which confirms the existence of a prolonged 'symptom tail' in PMR, wherein a significant number of patients receive a higher average daily dose, a larger total dose, more individual prescriptions of GC and receive their treatment over a longer period of time.
The reason behind this symptom tail could be a more severe subtype of PMR or a different underlying diagnosis, for example rheumatoid arthritis, for which referral for secondary care review may be appropriate. Alternatively, it may represent GCs masking the symptoms of other comorbidities which flare on reduction of GC treatment or adrenal insufficiency following prolonged GC use.
COnClusIOn And ClInICAl IMPlICATIOns
In conclusion, we have established the burden that PMR places on the UK health service. Due to the ageing population, the prevalence of PMR in the UK is increasing, although the incidence rates appear to have stabilised. Analysis of highquality, routinely collected primary care data has enabled us to confirm that a significant proportion of patients with PMR receive prolonged treatment with GC, contrary to previously held norms that cure will be achieved within 2 years. Long-term GC therapy is associated with a number of serious adverse effects, 22 which is both dose-dependent 30 and duration-dependent 31 . Early identification of patients who are likely to be subject to prolonged GC therapy is a priority area for future research. These patients could then be prioritised for referral to secondary care for consideration of GC-sparing agents. Funding rJp is funded by nHS research and Infrastructure funds. CdM is funded by the nIHr Collaboration for Leadership in Applied Health research and Care West Midlands, the nIHr School for primary Care research, and an nIHr research professorship in General practice, which also supports AAS (nIHr-rp-2014-04-026). tH is funded by an nIHr Clinical Lectureship in General practice. the views expressed are those of the authors and not necessarily those of the nHS, the nIHr or the department of Health. the funder was not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. disclaimer this study is based in part on data from the Clinical practice research datalink GoLd database obtained under licence from the UK Medicines and Healthcare products regulatory Agency. However, the interpretation and conclusions contained in this report are those of the author(s) alone.
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